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Background: Symptoms of allergic rhinitis (AR) have a detrimental effect on quality of life. The AR-Patient Benefit
Index (AR-PBI), a specific self-assessment tool has been developed to assess treatment-related benefit in two separate
sections: the Patient Needs Questionnaire (PNQ) which explores the patient’s expectations before treatment and the
Patient Benefit Questionnaire (PBQ) which evaluates treatment benefit. For the PNQ, three dimensions summarize
patients’ expectations: symptoms, social life and emotional state, thus covering a larger field than symptomatic relief.
The aim of the study was to validate the French language version of the AR-PBI and to assess the treatment-related
expectations and benefits provided in patients with allergic rhinitis treated with H1-antihistamines in a real-life study.
Methods: BENEFICA was a prospective, observational study involving patients with allergic rhinitis who were starting
treatment with H1-antihistamines. The Patient Needs Questionnaire (PNQ) was administered before treatment (D0) and
the Patient Benefit Questionnaire (PBQ) was collected after a 14-day course of H1-antihistamines (D15). Discomfort
(visual analog scale), and quality of life (miniRQLQ) were measured on D0 and D15.
Results: Three thousands and eighty-nine patients were enrolled in the study: mean age 39 ± 14 years, women 52%,
81% of patients with moderate to severe persistent rhinitis (Allergic Rhinitis and its Impact on Asthma, ARIA); 19% had
(a) concomitant condition(s), 18% were asthmatic, and 12% had atopic dermatitis. Discomfort and quality of life
improved between D0 and D15. AR-PBI was 2.7 ± 0.8, superior to 1 (threshold for clinically relevant benefit)
for 97% of patients and greater in patients willing to continue the treatment. PBI was moderately correlated
to change in miniRQLQ (r = −0.45, p < 0.0001) and change in discomfort (r = −0.38, p < 0.0001), suggesting a
richer conceptual content than symptoms relief.
Conclusions: The French version of the Allergic Rhinitis-Patient Benefit Index (AR-PBI) has been validated. It
complements the discomfort and quality of life tools and assesses the needs and benefits in patients suffering
from allergic rhinitis. This new tool may help physicians to better understand patients’ expectations and to
discuss treatment issues with their patients.
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Allergic rhinitis (AR) is one of the most common manifes-
tations of immunoglobulin E (IgE)-mediated inflammation
after allergen exposure of the nasal mucosa membrane. It
is clinically defined as a symptomatic disorder of the nose
characterized by the association of rhinorrhea, sneezing,
nose stinging, and nasal congestion, frequently associated
with symptoms such as conjunctival/pharyngeal stinging
and eye redness.
AR is very common in Western countries but it fre-
quently remains underdiagnosed [1]. In France, prevalence
was found to be 31% in adults in a well-conducted study
involving a representative random sample of more than
10,000 subjects [2]. Prevalence is higher in young people
and its frequency decreases with age [3].
AR impairs quality of life, sleep and social activities
[2,4]. It is a significant cause of reduced work productivity
and lost school days. Poor sleep quality may induce diur-
nal somnolence. Impact is correlated with the severity of
symptoms. AR is frequently associated with several co-
morbidities, including asthma, and physicians are encour-
aged to ask AR patients about symptoms of asthma [5].
Several medications are available for AR and they are
often prescribed in combination [6]. Antihistamines are
the most frequently prescribed drugs for relieving AR
symptoms [6] and are recommended as first-line therapy,
alone or in combination with intranasal steroids [7-9]. Pa-
tient’s satisfaction is a key for successful management of
allergic rhinitis improving compliance and clinical out-
comes in a virtuous cycle [10,11]. Patients’ expectations
may go, however, beyond symptomatic relief. Improving
patient’s satisfaction implies a better understanding of the
patient’s needs and a more accurate assessment of treat-
ment benefit from the patient’s point of view. Patients’
needs may, for example, include in-depth information on
the disease and its treatments as suggested by a study con-
ducted in patients with intermittent AR that found that
one out of five patients felt that they were poorly informed
about the disease [6]. Regarding benefits, going beyond
measurable efficacy to patient-relevant benefit is a new
paradigm. Generally speaking, patients want to see a reduc-
tion of morbidity, improvement of quality of life, a decrease
in symptoms and a decrease in treatment burden.
Recently, a new tool for the assessment of patient-defined
benefit in the treatment of allergic rhinitis has been pro-
posed and validated in English (AR-PBI for Allergic
Rhinitis-Patient Benefit Index) [12]. The questionnaire
consists of 25 non-redundant and non-overlapping items
assessing patient-relevant needs and benefits and is suited
for clinical practice and research. Patients with AR show a
large spectrum of needs regarding treatment. AR-PBI is
significantly correlated with treatment satisfaction, pa-
tient’s quality of life and treatment burden meaning that
the more satisfied and the less burdened the patients were,the higher the benefit was. The AR-PBI has proven to be
easy to understand.
The aim of the study was to validate the French lan-
guage version of the AR-PBI and to assess the treatment-
related expectations and benefits provided in patients with
allergic rhinitis treated with H1-antihistamines in a real-
life study.
Methods
Patient benefit index
The tool for the assessment of the patient benefit in AR
was initially adapted from a validated generic patient
benefit assessment tool in dermatology [13]. Items of the
generic tool were replaced by disease-specific items after
compilation of an item pool generated by patient inter-
views and reduction of the item pool by an expert panel of
physicians and patients. The final version includes 25 non-
redundant and non-overlapping items exploring patient-
relevant therapy needs and benefits. Patients are asked to
answer each of these 25 items at the start (Patient Needs
Questionnaire, PNQ) and at the end of treatment (Patient
Benefit Questionnaire, PBQ) on a five-point Likert scale.
Patient-relevant therapy needs are scaled from 0 ‘not im-
portant at all’ to 4 ‘very important’ with a response option
‘does not apply to me’. At end of treatment, patients are
asked to rate the extent of benefit achieved with the treat-
ment, scaled from 0 ‘treatment did not help at all’ to 4
‘treatment helped very much’. The Patient Benefit Index
(PBI) is a global score ranging from 0 to 4 computed by
dividing each rating on a need item by the sum of all ratings
in the PNQ, multiplying this fraction with the respective
benefit rating in the PBQ and summing these products. A
PBI ≥ 1 is considered as a threshold of ‘relevant benefit’ as
stated in a study of patients with psoriasis [12,14]. A French
version of the PBI was obtained after a translation-back
translation process [15].
Study design
A random sample of physicians was asked to partici-
pate in the observational, prospective, longitudinal study
BENEFICA. Physicians who volunteered to take part in
the study should ask the first 4 consecutive patients seen
in a routine visit who meet the inclusion criteria to enter
the study. Patients must be at least 18 years old and be
suffering from AR either documented by any relevant al-
lergen specific IgE and/or prick test within the previous
5 years or by presenting AR with a symptomatic rhinitis
occurring in a limited number of places at well-defined
times (a season, for example) or during specific circum-
stances (mowing the grass, for example). Patients should
not have been treated with antihistamines during the 8 days
prior to inclusion in the study and should be prescribed
with antihistamines on the day of inclusion. Antihista-
mines were administered orally. Given the observational
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which antihistamine to prescribe. Institution of concomi-
tant treatments with intranasal steroids, nasal vasocon-
strictors or antileukotrienes was not allowed. Patients
could however continue these treatments if they were
ongoing at entry. Patients undergoing allergen immuno-
therapy or who had taken any such treatment but discon-
tinued it less than 5 years ago were not allowed to enter
the study.
Collected data
Collected data included demographics, life habits, comor-
bidities frequently associated with AR (namely asthma, si-
nusitis, serous otitis media, urticaria, atopic dermatitis,
sinus or nasal polyposis, according to the physician’s know-
ledge). Symptoms including rhinorrhea, a blocked nose,
sneezing, nasal pruritus, eye pruritus, red eye, eye stinging,
watery eyes and pharyngeal discomfort were rated on a
4-level scale (0: no symptoms, 1: mild symptoms, 2: mod-
erate symptoms, 3: severe symptoms). AR was classified
according to ARIA with persistent rhinitis defined by
symptoms occurring for at least 4 days a week over at least
4 consecutive weeks during the last year. The physicians
gave details on the AR treatment history and on the treat-
ment that was prescribed at the end of the entry visit. Pa-
tients were provided with two sets of self-assessment
questionnaires and were instructed to complete the first
one at home immediately after the visit and before any
intake of the prescribed antihistamine. The second set
of self-assessment questionnaires was to be completed
at home 14 days later or earlier in the event of treatment
premature discontinuation. Both sets of self-assessment
questionnaires had to be returned separately using the
prepaid envelopes to the data center. Each set included
an evaluation of AR-related discomfort on a 10 cm
visual analog scale (0: no discomfort, 10: extreme dis-
comfort), the miniRQLQ (Rhinoconjunctivitis Quality of
Life Questionnaire, a 14-item questionnaire exploring the
negative impact on daily life caused by AR symptoms and
their consequences [16]), and either the PNQ for the first
set or the PBQ for the second set. The French versions of
the PNQ and PBQ are provided in the supporting infor-
mation (See Additional file 1: Tables S1 and S2). The som-
nolence item was individualized from the miniRQLQ with
negative impact on daily life rated on a 6-item scale (from
0: no negative impact on daily life to 6: huge negative im-
pact on daily life). Data collected by physicians and self-
assessment questionnaires were numbered similarly to
allow reconciliation before analysis.
Ethical considerations
This study was conducted in compliance with the Good
Clinical Practices protocol and Declaration of Helsinki
principles. In accordance with French law, formal approvalfrom an ethical committee is not required for observa-
tional studies. Patients gave oral consent to participate
after being informed about the study protocol by a writ-
ten information sheet. Oral consent was to be documented
in the patient’s medical file. The French “Commission
Nationale Informatique et Libertés” [Data Protection
Commission] gave its approval for the study.
Statistics
Internal consistency, construct validity and external consistency
of the French version of the AR-PBI were assessed. In-
ternal consistency was evaluated by the Cronbach α coeffi-
cient which is an estimate of the reliability of a
psychometric test, measuring if all items of the test are
measuring the same underlying concept. A value of 0.80
or more is generally considered as the proof of excellent
consistency. Construct validity was explored by principal
component analysis (Varimax rotation). Correlations
with change in miniRQLQ and discomfort (Pearson’s
correlation coefficients) explored external validity of the PBI
questionnaire. Patient-related needs (PNQ) and benefits
(PBQ) were described and the AR-PBI was calculated for
each patient. An AR-PBI ≥ 1 was used as the threshold of
“relevant benefit” [12,14]. Statistical significance of evolution
of discomfort and quality of life was tested by a Student’s t
test for paired samples.
The statistical analysis used SAS 9.3 software (SAS
Institute, Cary, NC, USA). Results are expressed as mean ±
SD or number and percentages.
Results
Patients
Three thousands and two hundred patients filled-in both
sets of self-assessment questionnaires. 111 out of 3200
patients did not meet the inclusion criteria. Therefore
the analysis was conducted on 3089 patients who have
been recruited by 912 physicians (general practitioners
84.6%, allergists 9.4%, other specialists 6.0%). Character-
istics of patients are displayed in Table 1. According to
the ARIA classification, rhinitis was mild and intermit-
tent in 1.9% of patients, moderate/severe and intermittent
in 10.3%, mild and persistent in 7.1%, moderate/severe and
persistent in 80.7%. Concomitant diseases were asthma in
18.3% of patients, sinusitis in 13.5%, serous otitis media in
1.4%, atopic dermatitis in 11.9%, and nasal or sinus polyps
in 5.5%.
Symptoms
At entry almost all patients presented rhinorrhea, sneezing
and nasal obstruction (respectively 99.4%, 99.2% and 98.2%).
Nasal pruritus was present in 96.4% of patients, eye prur-
itus in 89.4%, eye stinging in 84.9%, and watery eyes in
84.4%. Eye redness and pharyngeal discomfort were slightly
less frequent (78.7% and 77.0% respectively). Figure 1
Table 1 Patients’ characteristics
N = 3089
Age (years) 38.8 ± 13.7
Males 1481 (48.2%)
Active smokers 642 (20.8%)
Passive smokers 507 (16.4%)
Occupational exposure to allergens 416 (14.1%)
Duration of allergic rhinitis (years) 14.5 ± 11.0
Perennial rhinorrhea 668 (22.3%)
ARIA classification of rhinitis
Mild and intermittent 58 (1.9%)
Moderate and intermittent 314 (10.3%)
Mild and persistent 216 (7.1%)
Moderate and persistent 2463 (80.7%)
Concomitant diseases
Rhinosinusitis 418 (13.5%)
Sero-mucous otitis 43 (1.4%)
Nose or sinus polyps 170 (5.5%)
ENT disease* 588 (19.0%)
Asthma 565 (18.3%)
Atopic dermatitis 366 (11.9%)
Results are expressed as mean ± SD for continuous variables and as a number
(percentage) for categorical variables; *ENT disease includes rhinosinusitis,
serous otitis media, and nose or sinus polyps.
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Patients reported a discomfort level of 7.2 ± 1.4 with a
maximum of 10 and miniRQLQ was 46 ± 15 on a scale
ranging from 0 to 84 showing an impairment of quality of
life. Patients exhibited a mild degree of somnolence at
entry (2.6 ± 1.6 on a scale ranging from 0 to 6), higher in0.0%
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Figure 1 Intensity of symptoms at entry in the study (n = 3089). The p
reported on the horizontal axis, from left to right: rhinorrhea, a blocked no
pharyngeal discomfort. Symptom intensity (absent, mild, moderate, sev
absent; hatched columns correspond to mild; dotted columns correspopatients with persistent than in those with intermittent
rhinitis and more elevated in patients with severe symp-
toms than in patients with moderate symptoms.
Treatments prescribed at entry visit
All patients were prescribed with oral antihistamines
(99% bilastine), associated with a concomitant prescrip-
tion of glucocorticoids in 15.2% and cromones in 9.2%).
Self-reported compliance with antihistamine treatment
was excellent with 96.3% of patients stating that they
had taken the treatment regularly over the 14-day period
of the study.
Evolution of discomfort and quality of life
Quality of life significantly improved over the study period
whereas discomfort decreased (Table 2). The mean dis-
comfort level fell from 7.2 ± 1.4 to 3.1 ± 1.5 (p < 0.0001)
and miniRQLQ decreased from 46 ± 15 to 15 ± 12 (p <
0.0001). All dimensions improved: activities, practical
problems, nasal symptoms, eye disorders and other prob-
lems (p < 0.0001 for each dimension). The somnolence
score increased in 113 patients (3.7%). In these patients,
negative impact on daily life due to somnolence was mod-
erate in 23 patients (score 3/6), fair in 17 patients (score
4/6), significant in 20 patients (score 5/6) and very signifi-
cant in 5 patients (score 6/6).
Results from the AR- PBI
Acceptability
The AR-PBI elicited a good response from patients which
was adequate enough to produce significant data, since
the percentage of missing data never exceeded 1% for any
statement on the PNQ. As expected, there were differ-
ences in the ratings that the patients attributed to eachintensity
Absent
Mild
Moderate
Severe
ercentage of patients is reported on the vertical axis. Symptoms are
se, sneezing, nasal pruritus, red eye, eye stinging, watery eye,
ere) is represented by columns: white columns correspond to
nd to moderate; and black columns correspond to severe.
Table 2 Evolution of rhinitis over a 14-day course of
antihistamines
N = 3089
Baseline End of study
Discomfort (cm) 7.2 ± 1.4 3.1 ± 1.5*
MiniRQLQ 46.3 ± 14.5 14.7 ± 11.6*
Activities 11.0 ± 3.5 3.9 ± 3.0*
Practical problems 8.0 ± 2.2 2.7 ± 2.1*
Nasal symptoms 12.3 ± 3.3 4.0 ± 3.0*
Ocular symptoms 8.7 ± 4.7 2.4 ± 2.8*
Other problems 6.3 ± 4.3 1.8 ± 2.5*
Somnolence score 2.6 ± 1.6 0.8 ± 1.1*
Results are expressed as mean ± SD for continuous variables and frequency
(percentage in documented data) for categorical variables. Discomfort is
self-evaluated by the patient on a 10-cm visual analog scale; *p < 0.0001
between baseline and end of study.
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statements were important or unimportant. Depending on
the statement, the rate of “not concerned” patients varied
from 0.3% to 36.4%. The statement yielding the highest
percentage of “not concerned” responses was 36.4% for
“To feel less depressed”.
Patient’s needs
Patients’ expectations are detailed in Table 3. Among
afflicted patients (i.e. patients who did not select the re-
sponse “not concerned” to the statement), there was a
strong need to be healed (98.7%), not to have a runny nose
(97.8%), and to be able to breathe more freely via the nose
(97.1%). Relief from sneezing, nose stinging, burning or
watery eyes were also expectations which received high
mean ratings from the patients. Feeling less depressed, re-
suming a normal sexual life, spending less time on daily
treatment, being less dependent on Doctors and clinic
visits, or having fewer out-of-pocket treatment expenses
received lower mean ratings from the patients.
Patient-related benefits
AR-PBI was calculated in 3063 out of 3089 patients. They
achieved a mean AR-PBI of 2.7 ± 0.8 (median 2.8) ranging
from 0 to 4 (Figure 2). Applying a threshold of AR-PBI ≥ 1,
2956 patients (96.5%) received relevant benefit from anti-
histaminic treatment. Details on patient-related benefit
are provided in Table 4. Maximal benefits were obtained
for symptoms. There was no impact of tobacco consump-
tion (p = 0.73), occupational allergen exposure (p = 0.38)
on AR-PBI, nor of concomitant ENT disease (p = 0.85).
Construct validity and internal consistency
Principal component analysis showed that three factors
(social, physical and emotional) explained 67% of the
global PNQ variance (See Additional file 2: Table S3).These factors did not all carry the same weight. The so-
cial factor explained 51%, the physical factor explained
12% and the emotional factor explained 4% of the global
variance. Internal consistency was excellent (Cronbach
alpha 0.96) showing that all questions were measuring the
same underlying concept. Questions were not redundant,
as shown by the distribution of Pearson’s correlation coef-
ficients (See Additional file 3: Figure S1).
Concurrent validity
The AR-PBI was moderately correlated with changes in
discomfort and quality of life over the 14-day treatment
period (Pearson’s correlation coefficient −0.38 for discom-
fort and −0.45 for miniRQLQ, p < 0.0001 for both) sug-
gesting that the PBI had a larger conceptual scope and
measured more than symptoms and quality of life im-
provements. Change in discomfort and quality of life ex-
plained 21.3% of the AR-PBI global variance in a multiple
regression model. The population was divided in quintiles
according to PBI (Table 5). This showed that the higher
the discomfort and the more impaired the quality of life at
baseline, the higher the PBI would be (p < 0.0001). More-
over, patients with greater improvement in discomfort and
mini-RQLQ had a higher PBI.
AR-PBI in known sub-groups
Patients willing to pursue antihistamines after the 14-day
course (N = 2537) had a higher PBI score than the 94 pa-
tients willing to discontinue (2.7 ± 0.8 versus 1.4 ± 0.9, p <
0.0001). Patients reporting a worsening in negative impact
on daily life due to somnolence (N = 113) had a signifi-
cantly lower PBI (p < 0.0001) associated with poorer out-
come and poorer compliance.
Discussion
This study evaluated the properties of the French version
of AR-PBI, highlighted that patient-related benefit com-
prises more than solely symptomatic relief and underlined
the relationship between treatment-related benefit and
quality of life. AR-PBI was moderately correlated with im-
provement of quality of life or decrease in discomfort,
therefore complementing and not competing with the two
outcomes. In addition, this study provided new insights
on short-term patient-related benefits in patients receiving
antihistamine agents. The French AR-PBI has proven to
be well understood and easy to use by patients, as demon-
strated by the low number of missing responses.
Our study demonstrated that the French version of
AR-PBI has the same properties as the index English ver-
sion [12] despite methodological differences between the
validation methods. The index validation study was cross-
sectional with patients receiving various treatments and
some others being burden-free at the time of the study.
Conversely, our study was prospective and longitudinal
Table 3 Patients’ needs (PNQ before treatment initiation)
m± SD Percentage of
afflicted patients
Percentage of quite/very
important responses*
To be healed for all symptoms 3.5 ± 0.7 99.7% 98.7%
To no longer have a runny or blocked nose 3.4 ± 0.8 99.4% 97.8%
To be able to breathe through my nose more freely 3.3 ± 0.8 98.8% 97.1%
To not have sneezing impulses 3.1 ± 0.9 97.3% 93.3%
To not experience eye, nose or palate stinging anymore 3.1 ± 1.0 96.0% 92.3%
To be able to stay outdoors without symptoms 3.0 ± 0.9 96.8% 94.1%
To be able to engage in normal leisure activities 3.0 ± 1.0 94.9% 92.3%
To experience more enjoyment of life 2.9 ± 1.0 92.0% 89.8%
To have a treatment which is easy to use 2.9 ± 1.1 97.1% 89.2%
To have confidence in the therapy 2.9 ± 1.1 94.5% 89.1%
To not have burning or watery eyes anymore 2.9 ± 1.1 91.5% 87.8%
To be able to sleep better 2.8 ± 1.1 89.8% 84.6%
To be able to concentrate better at work 2.6 ± 1.1 80.1% 81.7%
To feel less fatigued or groggy 2.6 ± 1.2 89.6% 80.1%
To be more productive in everyday life 2.4 ± 1.2 82.2% 77.2%
To have fewer side effects 2.4 ± 1.2 79.5% 74.5%
To feel less burdened in your relationship 2.4 ± 1.2 82.8% 74.1%
To feel more comfortable in public 2.3 ± 1.2 83.9% 73.1%
To have no fear that the disease will become worse 2.3 ± 1.3 79.4% 72.8%
To be able to have a normal sex life 2.2 ± 1.3 66.0% 67.8%
To feel less depressed 2.2 ± 1.3 63.3% 66.9%
To feel less irritated 2.1 ± 1.2 76.8% 67.0%
To be less dependent on Doctor and clinic visits 2.1 ± 1.3 81.4% 65.0%
To spend less time on daily treatment 2.0 ± 1.3 79.8% 60.9%
To have fewer out-of-pocket treatment expenses 1.9 ± 1.4 74.2% 56.3%
Analysis of the Patient Needs Questionnaires (PNQ) filled in before treatment. Patients’ needs are ordered by decreasing importance. Needs are scaled from 0 ‘not
important at all’ to 4 ‘very important’; *percentage calculated in afflicted patients.
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Figure 2 AR-PBI distribution in patients with AR after a 14-day treatment period with antihistamines (n = 3089). The percentage of
patients is reported on the vertical axis while the patient benefit index (PBI) score is reported on the horizontal axis. This score ranges from 0 to 4
and is divided into 8 intervals.
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Table 4 Patients’ benefits related to current antihistamine treatment
mean ± SD* Percentage of patients
helped rather/a lot**
Weighted subscore
m ± SD***
To be healed for all symptoms 3.1 ± 0.9 92.8% 0.21 ± 0.11
To no longer have a runny or blocked nose 3.0 ± 0.9 91.9% 0.19 ± 0.11
To be able to breathe through my nose more freely 3.0 ± 1.0 91.6% 0.19 ± 0.11
To not have sneezing impulses 2.9 ± 1.0 89.9% 0.17 ± 0.10
To not experience eye, nose or palate stinging anymore 2.8 ± 1.0 88.0% 0.16 ± 0.10
To be able to stay outdoors without symptoms 2.9 ± 1.0 90.0% 0.16 ± 0.10
To be able to engage in normal leisure activities 2.8 ± 1.1 85.3% 0.15 ± 0.08
To have a treatment which is easy to use 2.7 ± 1.2 81.2% 0.14 ± 0.10
To experience more enjoyment of life 2.6 ± 1.2 81.8% 0.13 ± 0.08
To not have burning or watery eyes anymore 2.8 ± 1.1 85.0% 0.15 ± 0.09
To have confidence in the therapy 2.6 ± 1.2 80.5% 0.13 ± 0.09
To be able to sleep better 2.5 ± 1.3 76.0% 0.12 ± 0.09
To feel less fatigued or groggy 2.4 ± 1.2 75.6% 0.11 ± 0.07
To be able to concentrate better at work 2.4 ± 1.2 74.1% 0.10 ± 0.07
To be more productive in everyday life 2.4 ± 1.2 75.7% 0.10 ± 0.06
To feel less burdened in your relationship 2.3 ± 1.3 72.1% 0.09 ± 0.07
To have fewer side effects 2.2 ± 1.3 69.3% 0.09 ± 0.07
To have no fear that the disease will become worse 2.2 ± 1.3 69.2% 0.09 ± 0.07
To feel more comfortable in public 2.3 ± 1.3 72.2% 0.09 ± 0.07
To be able to have a normal sex life 2.0 ± 1.4 59.5% 0.08 ± 0.07
To feel less depressed 2.0 ± 1.3 62.0% 0.07 ± 0.06
To feel less irritated 2.1 ± 1.3 63.8% 0.07 ± 0.06
To be less dependent on Doctor and clinic visits 2.0 ± 1.3 63.2% 0.07 ± 0.06
To spend less time on daily treatment 2.0 ± 1.4 60.1% 0.07 ± 0.06
To have fewer out-of-pocket treatment expenses 1.8 ± 1.4 54.9% 0.06 ± 0.06
Global weighted PBI 2.7 ± 0.8
Patients with global PBI ≥1 2956 (96.5%)
Analysis of the Patient Benefits Questionnaires filled-in after antihistamine treatment. Patient’s benefits are ordered by decreasing importance of the corresponding
need. Treatment-related benefits are scaled from 0 ‘did not help at all’ to 4 ‘helped a lot’. *Data are described as mean ± SD. **Percentage of patients with the need
achieved by treatment from ‘rather helped’ to ‘helped a lot’ among afflicted patients at treatment initiation; ***PBI subscores weighted by the relative amount of the
corresponding patient’s need.
Table 5 Discomfort and mini-RQLQ at baseline and changes from baseline to end of study according to Patient Benefit
Index
Q1 Q2 Q3 Q4 Q5 p
N = 615 N = 602 N = 619 N = 613 N = 614
Global PBI 1.4 ± 0.5 2.3 ± 0.2 2.8 ± 0.1 3.1 ± 0.1 3.7 ± 0.2 -
[0.00-2.01] [2.01-2.57] [2.57-2.983] [2.983-3.384] [3.384-4.00]
Discomfort at baseline 6.7 ± 1.6 7.0 ± 1.4 7.2 ± 1.4 7.4 ± 1.3 7.5 ± 1.4 <0.0001
Mini RQLQ at baseline 40.3 ± 14.4 43.0 ± 13.3 46.8 ± 13.4 50.1 ± 14.1 51.5 ± 14.2 <0.0001
Change in discomfort at baseline compared to end of study −2.9 ± 1.9 −3.7 ± 1.7 −4.2 ± 1.6 −4.5 ± 1.8 −5.0 ± 1.9 <0.0001
Change in miniRQLQ at baseline compared to end of study −20.9 ± 15.5 −26.6 ± 13.0 −32.4 ± 13.6 −36.1 ± 15.2 −42.0 ± 15.4 <0.0001
Worsening in somnolence having a negative impact on daily life 55 (9.1%) 24 (4.0%) 14 (2.3%) 13 (2.1%) 7 (1.2%) <0.0001
The population was divided in quintiles (Q1 to Q5) according to PBI. PBI extent and mean value is described in each quintile. Changes in discomfort and quality of
life are calculated as change in 14-day value minus baseline so that improvements are expressed as negative values. Results are expressed as mean ± SD or number
(%). Comparisons used ANOVA for continuous variables or chi2 for categorical variables.
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being receiving antihistamines when entering the study.
All were prescribed with an antihistamine for 14 days.
Patients’ characteristics were similar between the two
studies, except for the sex ratio with 62.5% of women in
the index study. 87.8% of our patients suffered from persist-
ent rhinitis, a number higher than in the DREAMS (74%)
[17] and INSTANT studies [2] (50%). The INSTANT study
aimed at estimating the AR prevalence in the general popu-
lation whereas the DREAMS study was conducted in pa-
tients visiting ENT or allergy specialists for AR as in the
BENEFICA study. The DREAMS study recruited 76%
of patients with moderate to severe AR, a number sig-
nificantly lower than in our population (91%). Again the
difference could be due to our inclusion criteria which re-
quired antihistamines to be started at inclusion visit. We
found a 18.3% prevalence of asthma, a number slightly
lower than in other studies [2,3,18,19] but quite similar
to the DREAMS study (24%) [16]. Quality of life was
impaired in our study as already found in many studies
using various tools (SF36 [20], SF-12 [2], RQLQ [4,20] or
specific questionnaires exploring discomfort, consequences
for sleep, eating, mood, daily activities, occupation and leis-
ure activities [6]). In addition sleep disorders and somno-
lence have already been described in AR patients [2,21-23].
In a French cohort, the prevalence of sleep complaints
was one of 5 in mild AR, 1 out of 2 in moderate-severe
AR (and 18% in a control group). The prevalence of sleep
disorders (insomnia) was around 14% in mild AR and
40-42% in moderate-severe AR (and 16% in a control
group) [22].
The spectrum of patient’s needs was very large and ex-
tended beyond symptomatic relief. Correlations between
PBI and change in miniRQLQ or discomfort were sig-
nificant but moderate. Principal component analysis pro-
vided some keys for a better understanding of patient’s
needs. Indeed, the main dimension that explained 51%
of the global variance was related to social items such as
feeling less depressed, to be able to better concentrate
at work, to have no fear that the disease would become
worse, to be more productive, to feel more comfortable in
public, to feel less burdened in a relationship and to be
able to have a normal sex life. Clearly these expectations
extended further than solely symptomatic relief and thus
were not perceived by other tools including miniRQLQ.
In addition an “emotional” factor including items such as
feeling less fatigued or groggy, being able to sleep better,
experiencing more enjoyment of life and being able to en-
gage in normal leisure activities are not perceived to a suf-
ficient extent by other tools and must not be neglected.
Antihistamines proved to be very effective in relieving
symptoms and improving quality of life. Beyond these
well-known properties, antihistamines have been
demonstrated to produce a very substantial benefit fromthe patient’s perspective since almost all patients reported
a clinically relevant benefit defined by an AR-PBI ≥ 1. Nei-
ther anchor-based methods nor analyses based on PBI
distribution allow us to discuss this threshold which has
been proposed by the PBI authors [12]. Anchor-based
methods compare patients according to a clinical outcome
(improvement versus no change or deterioration for ex-
ample). Given that symptoms and discomfort dramatically
decreased over the study period in most patients, such
methods were not applicable. Applying methods based on
PBI distribution (such as half of standard deviation) [24],
we found a value of 0.4 which was even lower than the pro-
posed threshold. Antihistamines have exceeded the patient’s
expectations for improvement beyond symptomatic relief.
Our study has some limitations. Firstly, the population of
AR patients was not randomly selected but was constituted
from patients visiting a participating Doctor during the sur-
vey. Secondly physicians were not selected at random but
volunteered for the study. These limitations however are
unlikely to have influenced the results of the study because
patient needs and patient-defined benefit were not evalu-
ated by the physician but by the patient him/herself. Pa-
tients’ symptomatic profiles included the classic triad of
rhinorrhea, sneezing and nasal obstruction but the fre-
quency of these symptoms was higher than in other studies
conducted in France which reported a prevalence of 85%
for these symptoms versus 99% in our study. This could be
due to the inclusion criteria, which boosted selection of pa-
tients who were more symptomatic and who were actively
seeking effective treatment. Another limitation is the short
duration of the follow-up which was limited to 15 days. We
cannot assume that these short-term benefits would con-
tinue to exist if the follow-up was extended. The study was
not randomized and in real life observational conditions, it
was not possible to have a control group. Its first aim, how-
ever, was not to evaluate the benefits provided by anti-
histamines but to provide additional understanding of the
way that patients perceive these benefits and specifically to
explore dimensions other than symptomatic relief. This
study may help clinicians to understand why medication
may fail despite good symptomatic relief or why they may
succeed even if symptom relief is only modest. The lack of
a control group does not weaken these conclusions. Finally
self-assessment questionnaires were administered at home
and we cannot exclude the notion that some retrospective
completion may have occurred.
Conclusion
The French version of the AR-PBI has been validated.
AR-PBI allows the patient to estimate his own needs and
to assess the benefit of treatment in terms of his own ex-
pectations. This original point of view may complete the
usual tools assessing treatment efficacy including quality
of life questionnaires and clinical scores.
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Additional file 1: Table S1. French version of the PBI - Patient Needs
Questionnaire (PNQ). French version of the PBI – Patients Needs
Questionnaire (PNQ). Table S2. French version of the PBI - Patient
Benefit Questionnaire (PBQ). French version of the PBI – Patients
Benefit Questionnaire (PBQ).
Additional file 2: Table S3. Principal component analysis of the
patient’s needs in allergic rhinitis. Principal components analysis of the
patient’s needs (N = 3089). Patient’s needs are related to 3 factors: Factor
1- Social; Factor 2- Physical; Factor 3- Emotional. Items with higher correlation
coefficient to each factor are in bold.
Additional file 3: Figure S1. Distribution of Pearson’s correlation
coefficients between PNQ items. Distribution of Pearson’s correlation
coefficients for the questions of the Patient Needs Questionnaire (PNQ).
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